BMY Logo

Bristol-Myers Squibb Company (BMY) 

NYSE
Market Cap
$112.58B
Sector
Healthcare
Industry
Drug Manufacturers—General
Rank in Sector
122 of 776
Rank in Industry
1 of 10

Largest Insider Buys in Sector

BMY Stock Price History Chart

BMY Stock Performance

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients …

Insider Activity of Bristol-Myers Squibb Company

Over the last 12 months, insiders at Bristol-Myers Squibb Company have bought $773,049 and sold $38,931 worth of Bristol-Myers Squibb Company stock.

On average, over the past 5 years, insiders at Bristol-Myers Squibb Company have bought $5.89M and sold $35.35M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Samuels Theodore R. II (director) — $1.27M. BOERNER CHRISTOPHER S. (Chief Executive Officer) — $249,609. Hirawat Samit (EVP,Chief Med.Offr.,Drug Dev.) — $100,055.

The last purchase of 1,830 shares for transaction amount of $100,055 was made by Hirawat Samit (EVP,Chief Med.Offr.,Drug Dev.) on 2024‑11‑01.

List of Insider Buy and Sell Transactions, Bristol-Myers Squibb Company

2024-11-04SaleSVP and Controller
700
<0.0001%
$55.62$38,931-0.19%
2024-11-01PurchaseEVP,Chief Med.Offr.,Drug Dev.
1,830
<0.0001%
$54.67$100,055+2.08%
2023-12-05PurchaseChief Executive Officer
2,000
<0.0001%
$49.78$99,560-1.05%
2023-11-28PurchaseChief Executive Officer
3,071
0.0002%
$48.86$150,049+1.71%
2023-11-20Purchasedirector
8,500
0.0004%
$49.81$423,385+1.56%
2023-08-24SaleEVP, Chief Human Resources
17,986
0.0009%
$61.25$1.1M-17.67%
2023-08-03SaleEVP, Chief Research Officer
732
<0.0001%
$61.14$44,754-16.89%
2023-05-03SaleEVP & President, Research
50,385
0.0024%
$67.06$3.38M-19.35%
2023-02-06SaleBoard Chair and CEO
240,000
0.0115%
$74.65$17.92M-15.58%
2023-02-06SaleEVP, Chief Human Resources
11,183
0.0005%
$74.69$835,258-15.58%
2022-11-09SaleEVP, Chief Human Resources
16,250
0.0008%
$80.45$1.31M-15.55%
2022-11-07SaleEVP, Research & Early Dev.
45,910
0.0022%
$78.88$3.62M-14.63%
2022-09-20SaleBoard Chair and CEO
25,000
0.0012%
$69.71$1.74M+0.62%
2022-09-15SaleBoard Chair and CEO
50,000
0.0023%
$71.84$3.59M-2.19%
2022-09-14SaleEVP, Chief Human Resources
25,000
0.0012%
$70.75$1.77M-0.31%
2022-09-13SaleEVP, Chief Financial Officer
133,951
0.0063%
$71.30$9.55M-1.02%
2022-06-13SaleBoard Chair and CEO
30,000
0.0014%
$74.04$2.22M-0.89%
2022-06-06SaleEVP, General Counsel
65,000
0.003%
$74.89$4.87M-2.93%
2022-03-21SaleBoard Chair and CEO
25,000
0.0012%
$71.52$1.79M+5.53%
2022-03-16SaleEVP, Research & Early Dev.
31,331
0.0015%
$69.27$2.17M+7.64%

Insider Historical Profitability

10.62%
BOERNER CHRISTOPHER S.Chief Executive Officer
82672
0.0041%
$55.5121
Hirawat SamitEVP,Chief Med.Offr.,Drug Dev.
62109
0.0031%
$55.5110
Samuels Theodore R. IIdirector
35500
0.0018%
$55.5150+8.25%
CELGENE CORP /DE/10 percent owner
7008510
0.3456%
$55.5111+6.23%
SIGAL ELLIOTEVP, CSO & President R&D
148221
0.0073%
$55.51110+21.52%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
The Vanguard Group$10.09B9.18186.07M-6.1%-$655.79M0.19
BlackRock$8.82B8.02162.56M-3.3%-$300.58M0.19
State Street$4.97B4.5291.57M+2.38%+$115.23M0.2
JPMorgan Chase$4.82B4.3888.81M-1.37%-$66.93M0.43
Capital International Investors$3.81B3.4670.2M+14.1%+$470.46M0.77
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.